Radioiodine dosimetry with recombinant human thyrotropin Book Section
| Authors: | Tuttle, R. M.; Robbins, R. J. |
| Editors: | Wartofsky, L.; Van Nostrand, D. |
| Article/Chapter Title: | Radioiodine dosimetry with recombinant human thyrotropin |
| Abstract: | Although radioactive iodine (RAI) has been an essential tool in the management of thyroid cancer for more than 50 yr, there continues to be a lack of scientific rigor regarding the optimal choice of administered activity for individual patients. Often, activities of 30-150 mCi are administered for RAI remnant ablation, whereas activities ranging from 150-250 mCi are usually reserved for treatment of metastatic disease. In most cases, the activity selected is based on an empiric regimen without knowledge of the rate of RAI clearance for that individual patient. © 2006 Humana Press Inc. |
| Book Title: | Thyroid Cancer: A Comprehensive Guide to Clinical Management. 2nd ed |
| ISBN: | 978-1-58829-462-3 |
| Publisher: | Humana Press Inc |
| Publication Place: | Totowa, NJ |
| Date Published: | 2006-01-01 |
| Start Page: | 447 |
| End Page: | 451 |
| Language: | English |
| DOI: | 10.1007/978-1-59259-995-0_50 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Part IV -- Chapter 48 -- 9781588294623 (ISBN) -- Cited By (since 1996):1 -- Export Date: 28 May 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work